arXiv.itsnick.co

an independent field guide to 23 million papers from arXiv & OpenAlex — not affiliated with arXiv.org

Social Sciences · Demography

1998 Nov;46(4):
\n 
\n 
\n 
\n Quantification of prostaglandin D synthetase in cerebrospinal fluid: a potential marker for brain tumor.

SASO, Luciano, LEONE MG, SORRENTINO C, GIACOMELLI S, SILVESTRINI B, GRIMA J, LI JC, SAMY E, MRUK D, CHENG CY

· IRIS Research product catalog (Sapienza University of Rome)

See on the map

Abstract

Prostaglandin D synthetase (PGD-S; prostaglandin-H2 D-isomerase, EC 5,3,99,2), a 
\n30 kDa glycoprotein also known as beta-trace protein that catalyzes the formation
\nof prostaglandin D2 (PGD2) from PGH2, was purified to apparent homogeneity from
\nhuman cerebrospinal fluid (CSF) using a two-step procedure involving HPLC on a
\nVydac C8 reversed-phase column and high performance electrophoresis
\nchromatography (HPEC) using a 10% T SDS-polyacrylamide gel. The purity of PGD-S
\nisolated from CSF was confirmed by silver stained SDS-polyacrylamide gel and
\ndirect protein microsequencing (NH2-APEAQVSVQPNFQ). A highly specific polyclonal 
\nantibody was prepared against this protein for immunoassay development. Using an 
\nELISA, it was found that the concentration of PGD-S in CSF did not alter
\nsignificantly in different pathological conditions of the central nervous system 
\n(CNS). These include dementia (n = 9), hydrocephalus (n = 4), neuropathy (n =
\n11), optic neuritis (n = 4), multiple sclerosis (n = 11), and demyelinating
\nsyndrome (n = 11), when compared to normal individuals (n = 12); however, the
\nlevel of PGD-S in the CSF obtained from patients with brain tumor (n = 11), was
\nreduced by as much as 2-fold when compared to control samples (n = 12)
\nillustrating PGD-S is a potentially useful marker for brain tumor.

More like this